Fexofenadine 120mg Tablets are a solid oral pharmaceutical formulation containing Fexofenadine at a defined strength of 120mg per tablet. Development of this dosage form involves careful evaluation of the active pharmaceutical ingredient, excipient compatibility, powder flow, blend uniformity, compression characteristics, and finished-product performance. A controlled manufacturing approach helps maintain consistency across production batches. For pharmaceutical companies expanding their tablet portfolio, Fexofenadine 120mg Tablets can be incorporated into a structured PCD Pharma Franchise range with appropriate product specifications and quality documentation.
Formulation development begins with characterization of Fexofenadine and evaluation of its physical properties. Parameters such as particle size, bulk density, flowability, moisture content, and compressibility can influence the selection of manufacturing technology.
The excipient system is developed around the requirements of the final tablet. Diluents may be incorporated to provide suitable bulk and improve processing properties, while binders can support granule formation and tablet mechanical strength. Disintegrants may be selected according to the required dosage-form performance, with glidants and lubricants supporting powder flow and efficient tablet ejection.
Compatibility studies between Fexofenadine and the selected excipients may be conducted during the development stage. Such studies help evaluate physical or chemical interactions and support selection of an appropriate formulation composition.
The formulation is designed to provide a consistent distribution of the active pharmaceutical ingredient throughout the tablet matrix. Other characteristics, including tablet weight, dimensions, hardness, friability, and appearance, are established according to the finished-product specification.
Controlled raw-material handling is an essential part of manufacturing Fexofenadine 120mg Tablets. Each ingredient is received against established specifications, identified, tested where applicable, and dispensed according to the approved batch formula.
Depending on material characteristics, Fexofenadine and selected excipients may undergo sieving or milling to obtain a suitable particle-size range. Particle-size consistency can influence powder flow and reduce the possibility of segregation.
The blending process is designed to distribute Fexofenadine uniformly throughout the excipient system. The order of ingredient addition, mixer loading, blending time, and mixing speed are established during formulation development and maintained through controlled manufacturing procedures.
If low-quantity excipients or processing aids are incorporated, suitable premixing techniques may be used before their addition to the main blend. This can support more consistent distribution throughout the batch.
Representative samples may be collected from predefined locations within the blend and evaluated using an appropriate uniformity-testing procedure. Controlled transfer of the finished blend to the compression area helps minimize segregation during handling.
Depending on the powder characteristics, Fexofenadine 120mg Tablets may be manufactured using direct compression or an appropriate granulation process. Direct compression may be selected when the formulation demonstrates adequate flow and compaction properties.
When granulation is required, the process may involve controlled binder addition, granule formation, drying, sizing, and final lubrication. Drying parameters are carefully controlled because moisture content can affect granule strength, flowability, compression, and stability.
During tablet compression, parameters such as compression force, machine speed, feeder performance, and tooling configuration are monitored. In-process checks can include tablet weight, thickness, hardness, friability, and visual appearance.
A film-coating process may be incorporated depending on the approved product design. If coating is used, coating suspension preparation, spray rate, pan speed, inlet conditions, drying parameters, and coating weight gain are controlled to achieve a consistent finished surface.
The compression and coating stages are monitored through established in-process controls to maintain consistent tablet characteristics throughout the batch.
Quality control for Fexofenadine 120mg Tablets includes chemical, physical, and performance-related testing according to the approved product specifications. Identification and assay testing can be performed using suitable validated analytical procedures.
Dosage-unit uniformity is an important quality attribute for a solid oral dosage form. Representative tablets can be tested to confirm consistent distribution of Fexofenadine within the predefined acceptance criteria.
Dissolution testing may be performed under controlled laboratory conditions to characterize the release behavior of the finished tablet. Depending on the established specification, additional testing can include disintegration, hardness, friability, weight variation, thickness, moisture content, and related substances.
Analytical procedures should demonstrate appropriate specificity, accuracy, precision, and sensitivity for their intended application. Laboratory instruments should be qualified, calibrated, and maintained according to documented quality procedures.
Visual inspection can also be used to identify defects such as chipping, cracking, discoloration, coating irregularity, or other unacceptable physical characteristics.
All laboratory results, calculations, observations, and instrument records are documented as part of the batch quality file. Quality assurance review of the completed manufacturing and testing documentation supports the final release decision.
Stability studies are conducted to evaluate whether Fexofenadine 120mg Tablets maintain their established quality characteristics throughout the proposed shelf life. Studies may monitor assay, dissolution, related substances, physical appearance, moisture-related parameters, and other relevant attributes.
The formulation may be evaluated under defined long-term and accelerated stability conditions. Stability data help assess changes that may occur as a result of temperature, humidity, light, or other environmental factors.
Packaging selection is based on the product's stability requirements and intended distribution conditions. Suitable pharmaceutical-grade blister packs, strips, or container systems may be considered according to the approved product configuration.
Packaging compatibility studies may evaluate potential interaction between Fexofenadine tablets and the primary packaging material. Seal integrity and barrier characteristics can also be assessed where relevant.
The final pack should provide suitable protection during transportation, storage, and handling. Product labeling should include the approved product name, composition, strength, batch number, manufacturing information, expiry information, storage requirements, and other applicable regulatory particulars.
Proper packaging and controlled storage conditions help maintain the physical and chemical quality of the finished product throughout its intended shelf life.
Fexofenadine 120mg Tablets can be integrated into a diversified pharmaceutical tablet portfolio through standardized formulation development, controlled manufacturing, validated analytical procedures, and appropriate packaging systems. For companies operating in the PCD Pharma Franchise sector, maintaining consistent technical specifications supports organized product management across different markets.
A structured product-development file may include raw-material specifications, approved supplier information, formulation composition, manufacturing instructions, in-process controls, analytical methods, finished-product specifications, packaging details, and stability-study records.
Maintaining process control from raw-material dispensing through blending, granulation where applicable, compression, coating, packaging, and final quality review helps support batch-to-batch consistency.
Process validation can be used to demonstrate that established manufacturing parameters are capable of repeatedly producing tablets that meet predefined quality requirements. Deviation management, change control, equipment qualification, and documented standard operating procedures further support the overall pharmaceutical quality system.
For commercial portfolio management, the product composition and strength should remain consistent across product catalogs, packaging artwork, technical documents, and digital product listings.
Overall, Fexofenadine 120mg Tablets require coordinated control over API characterization, powder processing, blend uniformity, compression, coating where applicable, analytical testing, dissolution, stability, and packaging. A systematic quality framework across these stages supports the development of a consistent and professionally managed tablet formulation suitable for inclusion in a broader PCD Pharma Franchise portfolio.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech